INS and metabolic dysfunction-associated steatotic liver disease: In line with the improved NAFLD and hepatic function, HFD-induced glycometabolic disorder (e.g., adipose tissue weight, FBG, serum insulin, and HOMA-IR levels) was also alleviated by systemic injections of the miR-665-3p antagomir, yet exacerbated by the miR-665-3p agomir.